10.31

2.38% 0.24

After Hours: 10.29 -0.02 -0.19%

Xeris Biopharma Holdings Inc (XERS)

Overview News Price History Option Chain Financials Discussions Forecast

Xeris Biopharma Holdings Inc stock is traded at $10.31, with a volume of 2.29M. It is up +2.38% in the last 24 hours and up +32.52% over the past month. Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Previous Close:

$10.07

Open:

$10.04

24h Volume:

2.29M

Relative Volume:

0.94

Market Cap:

$1.88B

Revenue:

$314.85M

Net Income/Loss:

$12.01M

P/E Ratio:

157.40

EPS:

0.0655

Net Cash Flow:

$47.52M

1W Performance:

-1.62%

1M Performance:

+32.52%

6M Performance:

+68.46%

1Y Performance:

+12.80%

1-Day Range:

$9.8401

$10.33

1-Week Range:

$9.73

$10.55

52-Week Range:

$5.25

$11.33

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name

Xeris Biopharma Holdings Inc

Sector

Healthcare (1052)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

844-445-5704

Address

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Employee

435

Twitter

@XerisPharma

Next Earnings Date

2026-11-05

Latest SEC Filings

XERS's Discussions on Twitter

Compare XERS vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XERS Xeris Biopharma Holdings Inc	10.31	1.88B	314.85M	12.01M	47.52M	0.0655
TAK Takeda Pharmaceutical Co Adr	19.67	62.84B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.50	48.40B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	10.13	44.55B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	79.38	32.80B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	533.12	22.87B	3.17B	1.29B	1.01B	27.09

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Overweight
Aug-12-25	Resumed	H.C. Wainwright	Buy
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Mar-28-24	Initiated	Oppenheimer	Outperform
Aug-28-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Craig Hallum	Buy
Nov-17-21	Initiated	SVB Leerink	Outperform
Oct-29-21	Initiated	H.C. Wainwright	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-18-20	Initiated	Piper Sandler	Overweight
Jul-16-18	Initiated	Jefferies	Buy
Jul-16-18	Initiated	Leerink Partners	Outperform
Jul-16-18	Initiated	RBC Capital Mkts	Outperform

View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

Oct 13, 2026

Form 4 Xeris Biopharma Holdings, Inc: Steven Pieper (Officer) For: 1 October - Investing.com Nigeria

Oct 13, 2026

Xeris Biopharma CFO Steven Pieper sells $47,036 in stock By Investing.com - Investing.com Canada

Oct 13, 2026

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire

Oct 02, 2026

Oct 01, 2026

An officer plans a $159K share sale at Xeris Biopharma (XERS). - Stock Titan

Oct 01, 2026

Sep 29, 2026

Xeris Biopharma Holdings Insider Sold Shares Worth $250,000, According to a Recent SEC Filing - Yahoo Finance

Sep 29, 2026

Sep 28, 2026

A Xeris Biopharma (XERS) officer proposes a share sale valued at $637,000. - Stock Titan

Sep 28, 2026

Sep 18, 2026